Core Viewpoint - NeurAxis, Inc. is set to release its financial results for the third quarter of 2025 on November 11, 2025, before market open, followed by a conference call to discuss the results [1] Group 1: Financial Results Announcement - The financial results for the third quarter of 2025 will be reported on November 11, 2025, for the period ending September 30, 2025 [1] - A conference call is scheduled for the same day at 9:00 a.m. Eastern Time to review the financial results [1] Group 2: Conference Call Details - Interested parties can access the conference call via a live webcast available on the Company's Investor Relations website [2] - Participants can submit questions through the webcast portal or via email [2] Group 3: Company Overview - NeurAxis, Inc. focuses on neuromodulation therapies for chronic and debilitating conditions in both children and adults [4] - The Company is advancing its proprietary IB-Stim™ therapy, which is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 [4] - Additional clinical trials for PENFS technology are ongoing for various pediatric and adult conditions with significant unmet healthcare needs [4]

Core Viewpoint - NeurAxis, Inc. is actively engaging with investors through a webcast presentation and one-on-one meetings at the Lytham Partners Fall 2025 Investor Conference, highlighting its focus on neuromodulation therapies for chronic conditions [1][2][3]. Company Overview - NeurAxis, Inc. specializes in medical technology, particularly in neuromodulation therapies aimed at treating chronic and debilitating conditions in both children and adults [4]. - The company is advancing its proprietary IB-Stim™ therapy, which utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, and is FDA cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 years [4]. - NeurAxis is conducting additional clinical trials for PENFS targeting various pediatric and adult conditions with significant unmet healthcare needs [4].

Core Viewpoint - NeurAxis, Inc. has successfully closed a registered direct offering, raising approximately $5.0 million to strengthen its balance sheet and support growth initiatives, particularly for its IB-Stim therapy targeting chronic abdominal pain in pediatric patients [1][2]. Group 1: Financial Details - The offering consisted of 1,538,461 shares of common stock priced at $3.25 per share, resulting in gross proceeds of about $5.0 million before expenses [1]. - In addition to the offering, NeurAxis secured over $1 million from warrant exercises, further enhancing its financial position [2]. Group 2: Product and Market Impact - The recent FDA clearance for expanded indications of the IB-Stim treatment for Pediatric Functional Abdominal Pain (FAP) is a significant milestone for the company, addressing a critical need in pediatric care [2]. - The IB-Stim therapy is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21, with ongoing clinical trials for various pediatric and adult conditions [5]. Group 3: Future Outlook - The funds raised will be utilized to drive revenue growth for IB-Stim and prepare for the implementation of a CPT Category I code effective January 1, 2026, which is expected to enhance reimbursement and adoption of the therapy [2].